Literature DB >> 21840386

Paeoniflorin inhibits function of synoviocytes pretreated by rIL-1α and regulates EP4 receptor expression.

Yan Chang1, Lei Zhang, Chun Wang, Xiao-Yi Jia, Wei Wei.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: To investigate the effect of the Paeoniflorin (Pae), a main active component of total glucosides of paeony (TGP) extracted from the root of Paeonia lactiflora, on regulation of synoviocytes cultured from rats collagen-induced arthritis (CIA) in vitro.
MATERIALS AND METHODS: CIA was induced in male Sprague-Dawley rats immunized with chicken type II collagen (CCII) in Freund's complete adjuvant. The levels of interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), prostaglandin E(2) (PGE(2)) and cyclic adenosine monophosphate (cAMP) were measured by radioimmunoassay. The proliferation responses was determined by the 3-(4,5-2dimethylthiazal-2yl) 2,5-diphenyltetrazoliumbromide (MTT) assay. Expression of E-prostanoid (EP(4)) receptor was detected by Western blotting technique.
RESULTS: Treatment of Pae (2.5, 12.5, 62.5 μg/ml) significantly decreased the production of IL-1 and TNF-α. Recombinant interleukin-1 (rIL-1α) (10 ng/ml) apparently stimulated synoviocyte, thymocyte and splenocyte proliferation, and Pae (12.5, 62.5 μg/ml) inhibited abnormal proliferation responses stimulated by rIL-1α. Moreover, rIL-1α time- and concentration-dependently increased production of PGE(2). The production of PGE(2) produced by synoviocytes from CIA rats significantly inhibited by administration of Pae (12.5, 62.5 μg/ml). rIL-1α (10 ng/ml) decreased cAMP of synoviocytes cells treated for 24h. Similarly rIL-1α (0.1, 1, 10 ng/ml) induced a concentration-dependent decrease in the production of cAMP at 24h. Pae (12.5, 62.5 μg/ml) increased the production of cAMP in synoviocytes. The immunoblot, Pae (12.5, 62.5 μg/ml) apparently increased the expression of EP(4) receptor in synoviocytes stimulated by rIL-1α (10 ng/ml).
CONCLUSIONS: The present study indicates that Pae might exert its anti-inflammatory effects through suppressing synoviocytes function and regulating immune cells responses in CIA rats, which might be associated with its ability to up-regulate the E-prostanoid (EP(4)) receptor protein expression and modulate intracellular cAMP level.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840386     DOI: 10.1016/j.jep.2011.07.057

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  11 in total

1.  Paeoniflorin-6'-O-benzene sulfonate alleviates collagen-induced arthritis in mice by downregulating BAFF-TRAF2-NF-κB signaling: comparison with biological agents.

Authors:  Jin-Ling Shu; Xian-Zheng Zhang; Le Han; Feng Zhang; Yu-Jing Wu; Xiao-Yu Tang; Chen Wang; Yu Tai; Qing-Tong Wang; Jing-Yu Chen; Yan Chang; Hua-Xun Wu; Ling-Ling Zhang; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2018-11-16       Impact factor: 6.150

2.  Immunoregulatory Effects of Paeoniflorin Exerts Anti-asthmatic Effects via Modulation of the Th1/Th2 Equilibrium.

Authors:  Tianzhu Zhang; Zhaocong Yang; Shihai Yang; Juan Du; Shumin Wang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

3.  Paeoniflorin inhibits Th1 and Th17 cells in gut-associated lymphoid tissues to produce anti-arthritis activities.

Authors:  Fei Fei; Li-Xiang Aa; Qi Qi; Run-Bin Sun; Cai-Xia Yan; Ji-Ye Aa; Guang-Ji Wang
Journal:  Inflammopharmacology       Date:  2019-07-15       Impact factor: 4.473

4.  CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents.

Authors:  Feng Zhang; Jin-Ling Shu; Ying Li; Yu-Jing Wu; Xian-Zheng Zhang; Le Han; Xiao-Yu Tang; Chen Wang; Qing-Tong Wang; Jing-Yu Chen; Yan Chang; Hua-Xun Wu; Ling-Ling Zhang; Wei Wei
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

5.  The ROS/GRK2/HIF-1α/NLRP3 Pathway Mediates Pyroptosis of Fibroblast-Like Synoviocytes and the Regulation of Monomer Derivatives of Paeoniflorin.

Authors:  Zhongyang Hong; Xianzheng Zhang; Tianjing Zhang; Ling Hu; Ruijin Liu; Pan Wang; Han Wang; Qianqian Yu; Dan Mei; Ziyang Xue; Feng Zhang; Lingling Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-01-29       Impact factor: 6.543

Review 6.  The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis.

Authors:  Zhitao Feng; Juan Xu; Guochao He; Meiqun Cao; Lihong Duan; Liguo Chen; Zhengzhi Wu
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-10       Impact factor: 2.629

7.  CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage.

Authors:  Yan Chang; Xiaoyi Jia; Fang Wei; Chun Wang; Xiaojing Sun; Shu Xu; Xuezhi Yang; Yingjie Zhao; Jingyu Chen; Huaxun Wu; Lingling Zhang; Wei Wei
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

8.  A Modified Compound From Paeoniflorin, CP-25, Suppressed Immune Responses and Synovium Inflammation in Collagen-Induced Arthritis Mice.

Authors:  Jingyu Chen; Ying Wang; Huaxun Wu; Shangxue Yan; Yan Chang; Wei Wei
Journal:  Front Pharmacol       Date:  2018-06-07       Impact factor: 5.810

9.  CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells.

Authors:  Min Zhang; Mei Gao; Jinyu Chen; Lihua Song; Wei Wei
Journal:  Mol Med Rep       Date:  2019-10-23       Impact factor: 2.952

10.  A representative metalloprotease induces PGE2 synthesis in fibroblast-like synoviocytes via the NF-κB/COX-2 pathway with amplification by IL-1β and the EP4 receptor.

Authors:  Mariana N Viana; Elbio Leiguez; José M Gutiérrez; Alexandra Rucavado; Regina P Markus; Marina Marçola; Catarina Teixeira; Cristina M Fernandes
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.